Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Receives Average Recommendation of “Moderate Buy” from Analysts

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) has received an average recommendation of “Moderate Buy” from the nine research firms that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, five have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $8.75.

Several analysts recently issued reports on AUTL shares. HC Wainwright upped their price objective on shares of Autolus Therapeutics from $9.00 to $10.00 and gave the company a “buy” rating in a research note on Thursday, May 14th. Jefferies Financial Group raised shares of Autolus Therapeutics to a “strong-buy” rating in a research note on Monday, April 20th. Weiss Ratings upgraded Autolus Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, July 6th. Needham & Company LLC restated a “buy” rating and issued a $10.00 price target on shares of Autolus Therapeutics in a research report on Thursday, April 9th. Finally, Wall Street Zen raised Autolus Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, June 13th.

Institutional Trading of Autolus Therapeutics

Several large investors have recently added to or reduced their stakes in AUTL. GAMMA Investing LLC increased its stake in shares of Autolus Therapeutics by 115.6% in the 2nd quarter. GAMMA Investing LLC now owns 15,499 shares of the company’s stock worth $25,000 after acquiring an additional 8,309 shares during the last quarter. Independent Advisor Alliance acquired a new position in shares of Autolus Therapeutics during the 4th quarter valued at about $28,000. Marex Group plc acquired a new position in shares of Autolus Therapeutics during the 2nd quarter valued at about $28,000. Waverly Advisors LLC purchased a new stake in shares of Autolus Therapeutics in the first quarter valued at about $37,000. Finally, SmartHarvest Portfolios LLC purchased a new stake in shares of Autolus Therapeutics in the fourth quarter valued at about $43,000. 72.83% of the stock is currently owned by hedge funds and other institutional investors.

Autolus Therapeutics Stock Down 2.6%

Autolus Therapeutics stock opened at $1.49 on Friday. The company has a fifty day simple moving average of $1.57 and a 200-day simple moving average of $1.52. The firm has a market capitalization of $396.58 million, a price-to-earnings ratio of -1.37 and a beta of 2.04. Autolus Therapeutics has a 52-week low of $1.18 and a 52-week high of $2.52.

Autolus Therapeutics (NASDAQ:AUTL) last posted its quarterly earnings results on Friday, May 15th. The company reported ($0.27) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.02. The firm had revenue of $26.22 million for the quarter, compared to the consensus estimate of $26.27 million. Autolus Therapeutics had a negative net margin of 311.98% and a negative return on equity of 128.59%. On average, research analysts anticipate that Autolus Therapeutics will post -0.95 EPS for the current fiscal year.

About Autolus Therapeutics

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.